A designed peptide targeting CXCR4 displays anti-acute myelocytic leukemia activity in vitro and in vivo

Scientific Reports

Volumn 4, Issue , 2014, Pages

  Li, Xiaojin ^a   Guo, Hua ^a   Yang, Yanlian ^b   Meng, Jie ^a   Liu, Jian ^a   Wang, Chen ^b   Xu, Haiyan ^a  

^a INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

^b NATIONAL CENTER FOR NANOSCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; CXCL12 PROTEIN, HUMAN; CXCR4 PROTEIN, HUMAN; CYCLOPHOSPHAMIDE; PEPTIDE; STROMAL CELL DERIVED FACTOR 1;

ANIMAL; APOPTOSIS; CELL MOTION; DRUG EFFECTS; GENETICS; HUMAN; LEUKEMIA, MYELOID, ACUTE; METABOLISM; MOUSE; PATHOLOGY; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR CELL LINE; TUMOR MICROENVIRONMENT; UMBILICAL VEIN ENDOTHELIAL CELL;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL MOVEMENT; CHEMOKINE CXCL12; CYCLOPHOSPHAMIDE; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MICE; PEPTIDES; PHOSPHORYLATION; RECEPTORS, CXCR4; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

EID: 84930368054     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep06610     Document Type: Article

References (43)

1. Li, Z. W. & Dalton, W. S. Tumor microenvironment and drug resistance in hematologic malignancies. Blood Reviews 6, 333-342 (2006).
2. Konopleva, M., Konoplev, S., Hu, W., Zaritskey, A. Y., Afanasiev, B. V. & Andreeff, M. Stromal cells prevent apoptosis of AML cells by up-regulation of anti-apoptotic proteins. Leukemia. 16, 1713-1724 (2002).
3. Manabe, A., Coustan-Smith, E., Behm, F.G., Raimondi, S.C.& Campana, D. Bone marrow-derived stromal cells prevent apoptotic cell death in B-lineage acute lymphoblastic leukemia. Blood 79, 2370-2377 (1992).
4. Panayiotidis, P., Jones, D., Ganeshaguru, K., Foroni, L. & Hoffbrand, A. V. Human bone marrow stromal cells prevent apoptosis and support the survival of chronic lymphocytic leukaemia cells in vitro. Br J Haematol. 92, 97-103 (1996).
5. Zeng, Z. et al. Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Blood 113, 6215-24 (2009).
6. Burger, J. A., Tsukada, N., Burger, M., Zvaifler, N. J., Dell'Aquila, M. & Kipps, T. J. Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood 96, 2655-2663 (2000).
7. Imai, K. et al. Selective secretion of chemoattractants for haemopoietic progenitor cells by bone marrow endothelial cells: a possible role in homing of haemopoietic progenitor cells to bone marrow. Br J Haematol. 106, 905-911 (1999).
8. Burger, J. A. & Kipps, T. J. CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood 107, 1761-1767 (2006).
9. Burger, J. A. & Bürkle, A. The CXCR4 chemokine receptor in acute and chronic leukaemia: a marrow homing receptor and potential therapeutic target. Br J Haematol. 137, 288-296 (2007).
10. Tavor, S. et al. CXCR4 regulates migration and development of human acute myelogenous leukemia stem cells in transplanted NOD/SCID mice. Cancer Res. 64, 2817-2824 (2004).
11. Burger, J. A., Burger, M. & Kipps, T. J. Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells. Blood 94, 3658-3667 (1999).
12. Sipkins, D. A. et al. In vivo imaging of specialized bone marrow endothelial microdomains for tumour engraftment. Nature 435, 969-973 (2005).
13. Lagneaux, L., Delforge, A., Bron, D., De Bruyn, C. & Stryckmans, P. Chronic lymphocytic leukemia Bcells but not normal Bcells are rescued from apoptosis by contact with normal bone marrow stromal cells. Blood 91, 2387-2396 (1998).
14. Burger, J. A. & Peled, A. CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers. Leukemia 23, 43-52 (2009).
15. Murakami, T. et al. A small molecule CXCR4 inhibitor that blocks T cell line-tropic HIV-1 infection. J Exp Med. 186, 1389-1393 (1997).
16. Juarez, J., and Bradstock, K. F., Gottlieb, D. J. & Bendall, L. J. Effects of inhibitors of the chemokine receptor CXCR4 on acute lymphoblastic leukemia cells in vitro. Leukemia 17, 1294-1300 (2003).
17. Juarez, J. et al. CXCR4 antagonists mobilize childhood acute lymphoblastic leukemia cells into the peripheral blood and inhibit engraftment. Leukemia 21, 1249-1257 (2007).
18. Burger, M. et al. Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells. Blood 106, 1824-1830 (2005).
19. Kawaguchi, A. et al. Inhibition of the SDF-1alpha-CXCR4 axis by the CXCR4 antagonist AMD3100 suppresses the migration of cultured cells from ATL patients and murine lymphoblastoid cells from HTLV-I Tax transgenic mice. Blood 114, 2961-2968 (2009).
20. Nervi, B. et al. Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100. Blood 113, 6206-6214 (2009).
21. Parameswaran, R., Yu, M., Lim, M., Groffen, J. & Heisterkamp, N. Combination of drug therapy in acute lymphoblastic leukemia with a CXCR4 antagonist. Leukemia 25, 1314-1323 (2011).
22. Weisberg, E. et al. Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow microenvironment and sensitizes them to nilotinib. Leukemia 26, 985-90 (2012).
23. Zeng, Z. et al. Inhibition of CXCR4 with the novel RCP168 peptide overcomes stroma-mediated chemoresistance in chronic and acute leukemias. Mol Cancer Ther. 5, 3113-21 (2006).
24. Kuhne, M. R. et al. BMS-936564/MDX-1338: afully human anti-CXCR4 antibody induces apoptosis in vitro and shows antitumor activity in vivo in hematologic malignancies. Clin Cancer Res. 19, 357-66 (2013).
25. Domanska, U. M. et al. A reviewon CXCR4/CXCL12 axis in oncology: no place to hide. Eur J Cancer. 49, 219-230 (2013).
26. Juarez, J., Bendall, L. & Bradstock, K. Chemokines and their receptors as therapeutic targets: the role of the SDF-1/CXCR4 axis. Curr Pharm Des. 10, 1245-1259 (2004).
27. Bleul, C. C., and Fuhlbrigge, R. C., Casasnovas, J. M., Aiuti, A. & Springer, T. A. A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1). J Exp Med. 184, 1101-1109 (1996).
28. Jo, D. Y., and Hwang, J. H., Kim, J. M., Yun, H. J. & Kim, S. Human bone marrow endothelial cells elaborate non-stromal-cell-derived factor-1 (SDF-1)-dependent chemoattraction and SDF-1-dependent transmigration of haematopoietic progenitors. Br J Haematol. 121, 649-652 (2003).
29. Shen, W., and Bendall, L. J., Gottlieb, D. J. & Bradstock, K. F. The chemokine receptor CXCR4 enhances integrin-mediated in vitro adhesion and facilitates engraftment of leukemic precursor-B cells in the bone marrow. Exp Hematol. 29, 1439-1447 (2001).
30. Peled, A. et al. The chemokine SDF-1 activates the integrins LFA-1, VLA-4, and VLA-5 on immature human CD34 (1) cells: role in transendothelial/stromal migration and engraftment of NOD/SCID mice. Blood 95, 3289-3296 (2000).
31. Glodek, A. M. et al. Focal adhesion kinase is required for CXCL12-induced chemotactic and pro-adhesive responses inhematopoietic precursor cells. Leukemia 21, 1723-1732 (2007).
32. Fei, F., Stoddart, S., Müschen, M., and Kim, Y. M., Groffen, J. & Heisterkamp, N. Development of resistance to dasatinib in Bcr/Abl-positive acute lymphoblastic leukemia. Leukemia. 24, 813-820 (2010).
33. Voermans, C., and Anthony, E. C., Mul, E., van der Schoot, E. & Hordijk, P. SDF-1-induced actin polymerization and migration in human hematopoietic progenitor cells. Exp Hematol. 29, 1456-1464 (2001).
34. Bendall, L. J., Baraz, R., Juarez, J., Shen, W. & Bradstock, K. F. Defective p38 mitogen-activated protein kinase signaling impairs chemotaxic but not proliferative responses to stromal-derived factor-alpha in acute lymphoblastic leukemia. Cancer Res. 65, 3290-3298 (2005).
35. Tavor, S. & Petit, I. Can inhibition of the SDF-1/CXCR4 axis eradicate acute leukemia. Semin Cancer Biol. 20, 178-185 (2010).
36. Konoplev, S. et al. Overexpression of CXCR4 predicts adverse overall and event-free survival in patients with unmutated FLT3 acute myeloid leukemia with normal karyotype. Cancer. 109, 1152-1156 (2007).
37. Rombouts, E. J., Pavic, B., Lowenberg, B. & Ploemacher, R. E. Relation between CXCR-4 expression, Flt3 mutations, and unfavorable prognosis of adult acute myeloid leukemia. Blood 104, 550-557 (2004).
38. Spoo, A. C., Lübbert, M., Wierda, W. G. & Burger, J. A. CXCR4 is a prognostic marker in acute myelogenous leukemia. Blood 109, 786-791 (2007).
39. Trent, J. O. et al. Lipid bilayer simulations of CXCR4 with inverse agonists and weak partial agonists. J Biol Chem. 278, 47136-47144 (2003).
40. Zhang, W. B. et al. A point mutation that confers constitutive activity to CXCR4 reveals that T140 is an inverse agonist and that AMD3100 and ALX40-4C are weak partial agonists. J Biol Chem. 277, 24515-24521 (2002).
41. Mao, X. B. et al. Binding modes of thioflavin t molecules to prion peptide assemblies identified by using scanning tunneling microscopy. ACS Chemical Neuroscience. 2, 281-287 (2011).
42. Mao, X. B. et al. Beta structure motifs of islet amyloid polypeptides identified through surface-mediated assemblies. PNAS. 108, 19605-19610 (2011).
43. Wang, C. X. et al. Determination of relative binding affinities of labeling molecules with amino acids by using scanning tunneling microscopy. Chemical Communications. 47, 10638-10640 (2011).